Frontlight ResearchEarly access
Enrolling by invitationPhase 4
Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients
Key facts
- Who runs it
- Ann & Robert H Lurie Children's Hospital of Chicago
- Where
- Chicago and Cincinnati, United StatesSee the 3 sites
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 4
- People taking part
- 80 people, planned
- Started
- 18 Mar 2024
- Expected to end
- 30 Sept 2028
- Type of study
- Interventional
- Treatments tested
- Recombinant Zoster Vaccine
- Record updated
- 27 March 2026
Who can take part
- Age
- 19 years to 40 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- 19 years of age or older and willing to provide written informed consent for the study participation
- Prior recipient of solid organ transplant more than one year prior to participation
- Stable immunosuppressive medication regimen for last 6 months prior to participation
- Participant must have a working telephone number, email address or patient Electronic Health Record (EHR) portal access and be willing to be contacted for study follow-up by any of these means
- For participants of childbearing potential, use of effective pregnancy prevention till 2 months post last dose
Who cannot take part
- Active treatment with corticosteroids or other immunosuppressive agents for acute or chronic rejection
- More than 2 courses of treatment for acute rejection within last 2 years prior to study enrollment
- History of anaphylaxis or other allergic reaction after receiving prior vaccinations or vaccine components
- Receipt of any inactivated vaccine 8 days before/after dose #1, subunit vaccine 14 days before/after dose #1 and live, attenuated or mRNA vaccine 30 days before/after dose #1
- History of herpes zoster, primary varicella or VZV vaccination within past 1 year prior to study entry
- Active pregnancy as defined by positive pregnancy test at the time of screening and prior to each dose of vaccine
- Febrile illness with Temp ≥39°C and/or infection that require hospitalization or oral antibiotics/antivirals/antifungal/anti-parasite medication within 14 days prior to day 1
- Any condition that, in the opinion of the investigator, may interfere with optimal participation in the study
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 19 and 40 years old?
Where in United States
- Ann & Robert H. Lurie Children's HospitalChicago, United StatesEnrolling by invitation
- Northwestern Memorial HospitalChicago, United StatesEnrolling by invitation
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This goal of this study is to assess the safety and immunogenicity of recombinant zoster virus in young adult solid organ transplant recipients. In this study, participants will receive the recombinant zoster vaccine. They will be monitored for adverse events and tested for antibody and cellular immunity.
The group in the trial
- Recombinant Zoster Vaccine Administration and TestingTreatment being tested
all participants will receive 2 doses of recombinant zoster vaccine (Shingrix)
Treatment: Recombinant Zoster Vaccine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT06162494, who can take part
- Record updated
- 27 March 2026